The predictive significance of anti-RO-52 antibody in patients with interstitial pneumonia after treatment of malignant tumors
Year: 2025
Type: article
Study design: Observational Study
Abstract: Aim: To discover the predictive indicators of the risk of interstitial lung disease (ILD) after treatment of malignant tumors from myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies (MAA) and explore possible predictive value and significance. Methods: A total of 73 patients hospitalized in the Shulan (Hangzhou) Hospital from January 2020 to March 2021 were screened retrospectively, they all completed the MSA and MAA, and the imaging was consistent with changes in ILD. We analyzed the characteristics of MSA and MAA in tumor patients and non-tumor patients, and the characteristics of MSA and MAA positive in patients with ILD after treatment. Results: A total of 58 patients with ILD were diagnosed, 19 patients (32.76%) with malignant tumors, 16 patients with positive MSA or MAA (84.21%), of which 10 (50%) patients had anti-RO-52 antibodies. After treatment, 12 cases (46.15%) developed ILD and 10 cases (90.91%) had a positive spectrum of specific inflammatory diseases. Conclusion: The MSA and MAA may have a predictive effect on people who are prone to ILD during the treatment of malignant tumors, and the anti-RO-52 antibody may be an important predictive antibody index.
Source: Open Medicine
Authors: Zongyu Li, Li Yang, Yan Zhu, Shengli Ye, Xin Fang, Qiuping Xu
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,373
OpenAlex ID: W4412930650